Cecilia Brown

DocwireNews

The US Food and Drug Administration announced it has approved pembrolizumab (Keytruda, Merck) plus pemetrexed and platinum chemotherapy as a first-line treatment for unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
The efficacy of the combination was evaluated in KEYNOTE-483, a randomized, open-label trial including patients with unresectable advanced or metastatic MPM who had not received prior systemic therapy for advanced or metastatic disease.
Trial investigators randomized patients 1:1 to receive pembrolizumab for up to 2 years in combination with pemetrexed and platinum-based chemotherapy for up to 6 cycles (n=222) or pemetrexed and platinum-based chemotherapy for up to 6 cycles (n=218).
KEYNOTE-483 showed a statistically significant improvement in overall survival (OS), which was the main efficacy outcome measure of the trial, in patients receiving pembrolizumab with chemotherapy (median OS, 17.3 months) compared to those who received chemotherapy alone (median OS, 16.1 months; hazard ratio [HR], 0.79; P=.0162).
The median progression-free survival was 7.1 months (95% CI, 6.9-8.1) in those receiving the combination therapy and 7.1 months (95% CI, 6.8-7.7) in those receiving chemotherapy alone (HR, 0.80 [95% CI: 0.65, 0.99]; P=.0194).
The confirmed overall response rate was 52% (95% CI, 45.5-59.0) in patients receiving pembrolizumab plus chemotherapy, compared to 29% (95% CI, 23.0-35.4) in those receiving chemotherapy alone. The median duration of response was 6.9 months (95% CI: 5.8, 8.3) in those receiving the combination therapy and 6.8 months (95% CI: 5.5, 8.5) in those receiving chemotherapy alone.
The recommended pembrolizumab dose is 200 mg every 3 weeks or 400 mg every 6 weeks until disease progression or unacceptable toxicity for up to 2 years.
“Adverse reactions occurring in patients with MPM were similar to those receiving pembrolizumab with pemetrexed and platinum chemotherapy,” according to FDA officials. The full prescribing information will be posted on <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">Drugs@FDA</a>.
Source: <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-unresectable-advanced-or-metastatic-malignant-pleural" target="_blank" rel="noopener">FDA</a>

Rob Dillard

Study Finds a Significant Correlation Between Amyloidosis and Atrial Fibrillation

AHA 2024: CardioNerds

Analyzing the Use of a Multimodal Deep Learning Model for Detecting Transthyretin Cardiac Amyloidosis

The Readability of Online Patient Information for Cardiac Amyloidosis is Lacking

Latest News

FDA Approves Pembrolizumab Plus Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Mesothelioma

The FDA approved pembrolizumab (Keytruda) plus pemetrexed and platinum chemotherapy as first-line treatment for unresectable advanced or metastatic malignant pleural mesothelioma.

FDA Approves Pembrolizumab Plus Chemotherapy for Malignant Pleural Mesothelioma

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe